Clark Golestani

Clark Golestani's work experience includes various roles in advisory services, private equity, and investment advising. In 2018, they became the Managing Director at C Sensei Group LLC, where they focused on advising companies in the healthcare, life sciences, and technology sectors. Clark also served as a Senior Advisor at New Mountain Capital, a private equity firm targeting businesses in "defensive growth" industries.

In 2020, Golestani took on roles as an Investment Advisor at both the K2 Access Fund and The CXO Fund. These venture funds focus on early-stage startups and provide assistance with product-market fit and customer acceleration. Additionally, they joined the Drug Information Association as Co-Chair of the Science and Policy Advisory Council.

Golestani also served as a Director on the Board of Directors for three companies in 2020: emids, a digital transformation solutions provider for the healthcare industry; Molecula, a company specializing in enabling global enterprises through advanced blockchain technology; and Zapata Computing, Inc., a company involved in quantum computing.

In 2021, Golestani joined the Board of Directors for ToposWare Inc., which is developing an advanced blockchain ecosystem with a focus on data privacy and tamper resistance.

Finally, in 2023, they joined the Board of Directors for Emmes, a leading clinical research organization dedicated to biopharmaceutical development and human health goals. Emmes emphasizes scientific excellence, collaboration, and problem-solving to improve the quality of research and treatment options in healthcare.

Clark Golestani has a degree in SB from the Sloan School of Management at the Massachusetts Institute of Technology. No information is provided regarding the start or end year of their education at this institution.